Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer

NCT00696696 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Gemcitabine
DRUG: Erlotinib
DRUG: Sorafenib

Sponsor

NYU Langone Health

Collaborators

[object Object]
[object Object]